SCHEDULE: Deep Track Capital Cuts Autolus Therapeutics Stake Below 1%

Deep Track Capital and affiliates have reduced their beneficial ownership in Autolus Therapeutics plc to 0.97%, falling below the 5% threshold.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin (collectively, "Deep Track") have filed an Amendment No. 4 to their Schedule 13G regarding Autolus Therapeutics plc.
• As of September 30, 2025, Deep Track beneficially owns 2,568,613 American Depositary Shares (ADS) of Autolus Therapeutics plc.
• This ownership represents 0.97% of the total class of securities outstanding.
• The percentage is calculated based on 266,141,411 ordinary shares outstanding as of August 11, 2025, as reported in Autolus Therapeutics' 10-Q filed on August 12, 2025.
• Deep Track holds shared voting power and shared dispositive power over all 2,568,613 shares.
• The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: The reduction of Deep Track Capital's stake in Autolus Therapeutics plc to below 1% from a previous position above 5% is generally viewed as a negative signal by the market, indicating a potential loss of confidence or strategic shift by a major investor.

Negatives

• A significant institutional investor, Deep Track Capital, has reduced its beneficial ownership in Autolus Therapeutics plc from above 5% to 0.97%.
• This reduction below the 5% reporting threshold may signal a decreased conviction in the company's future prospects or a reallocation of capital by the investor.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the reduction in institutional ownership as a negative signal, potentially impacting share price and investor confidence.

Key Dates

Recommendation

While the reduction in a significant institutional stake is a negative signal, this filing alone does not provide enough information to warrant a strong sell recommendation. It suggests caution and warrants further investigation into the reasons for the reduction and the company's current fundamentals. A "hold" recommendation allows investors to assess additional information before making a definitive decision.

Keywords

Autolus Therapeutics, Deep Track Capital, Schedule 13G, beneficial ownership, institutional investor, ADS, equity stake, biotech